Intellia Therapeutics Inc
Change company Symbol lookup
Select an option...
NTLA Intellia Therapeutics Inc
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company. The Company is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The Company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned T cell receptor (TCR)-T cell candidate, NTLA-5001 for the treatment of acute myeloid leukemia (AML) and hematopoietic stem cells (HSCs) for the treatment of sickle cell disease.

Postmarket

Last Trade
Delayed
$42.98
0.54 (1.27%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$42.44
Day's Change
2.32 (5.78%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
42.69
Day's Low
40.27
Volume
(Below Average)
Volume:
1,042,423

10-day average volume:
1,256,801
1,042,423

Chewy Announces Fiscal Third Quarter 2022 Financial Results Conference Call

4:05 pm ET November 17, 2022 (BusinessWire) Print

Chewy, Inc. (NYSE: CHWY) ("Chewy"), a trusted destination for pet parents and partners everywhere, today announced it will report fiscal third quarter 2022 financial results after the market close on Thursday, December 8, 2022. Management will host a conference call and webcast to discuss the company's financial results at 5:00 pm ET.

Chewy Fiscal Third Quarter 2022 Financial Results Conference Call When: Thursday, December 8, 2022 Time: 5:00 pm ET Conference ID: 954550 Live Call: 1-844-200-6205 (US Toll-Free), 1-646-904-5544 (US Local), or +1-929-526-1599 (International) Replay: 1-866-813-9403 (US Toll-Free), 1-929-458-6194 (US Local), +44-204-525-0658 (International) Replay Access Code: 836051 (The replay will be available approximately two hours after the completion of the live call until 11:59 pm ET on December 15, 2022) Webcast: https://investor.chewy.com

About Chewy

Our mission is to be the most trusted and convenient destination for pet parents (and partners) everywhere. We believe that we are the preeminent online source for pet products, supplies, and prescriptions as a result of our broad selection of high-quality products and services, which we offer at competitive prices and deliver with an exceptional level of care and a personal touch to build brand loyalty and drive repeat purchasing. We continually develop innovative ways for our customers to engage with us, and partner with more than 3,000 of the best and most trusted brands in the pet industry offering more than 100,000 products, to bring a high-bar, customer-centric experience to our customers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117006021/en/

SOURCE: Chewy, Inc.

Media Contact: 
Diane Pelkey
dpelkey@chewy.com

Investor Contact: 
Robert LaFleur
ir@chewy.com
comtex tracking

COMTEX_419121133/1006/2022-11-17T16:05:04

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.